maci remains available without interruption

The past few months have brought unprecedented challenges and stress to all Americans and others around the globe. At Vericel Corporation, our thoughts are with those affected by COVID-19 and we are especially thankful to all healthcare workers for their critical efforts during this challenging time.

Our mission to help treat patients with serious knee cartilage injuries has remained steadfast throughout the pandemic. Vericel continues to manufacture MACI® (autologous cultured chondrocytes on porcine collagen membrane) for those in need of care. MACI is aseptically manufactured in an FDA licensed facility using sterile materials and reagents. Our clean rooms maintain the highest cleanliness standards through automated environmental controls and monitoring. A rotational cleaning program of the room and all work surfaces includes quality control testing and release of the rooms. All Vericel manufacturing personnel wear pre-sterilized gowning materials. Laminar flow biosafety cabinets located within the clean rooms are used for all manufacturing processes. Each phase of manufacturing is monitored and tested for microbial contamination. Following manufacturing, all final products undergo rigorous quality control testing including the use of numerous proprietary release assays to ensure that our products are safe, consistent, and free of microbial contaminants.



As restrictions due to COVID-19 ease, surgeons and physicians may begin allowing patients back into their offices. In many cases, telehealth options for office visits or physical therapy may also be available. Physician’s office protocols vary by location and facility. Patients should contact their individual physician’s office for specific guidance.

To find a MACI Specialist in your area, please click here. For MACI-biopsied patients, the MyCartilageCare® support program remains available to assist with insurance approval coordination and treatment information. Visit for more information.


PP.US.MAC.1026 v3.0